Epidermolysis Bullosa Acquisita Latest Advances

Find the Latest Research About Epidermolysis Bullosa Acquisita

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 852 publications

Epidermolysis bullosa acquisita improved with use of dupilumab.

Epidermolysis bullosa acquisita improved with use of dupilumab.

Journal: JAAD case reports

Published: July 03, 2026

Highlights from JAAD Case Reports: August 2026.

Highlights from JAAD Case Reports: August 2026.

Journal: Journal of the American Academy of Dermatology

Published: May 26, 2026

The Therapeutic Challenge in a Rare Case of Immunoglobulin A Type of Epidermolysis Bullosa Acquisita.

The Therapeutic Challenge in a Rare Case of Immunoglobulin A Type of Epidermolysis Bullosa Acquisita.

Journal: Indian journal of dermatology

Published: May 11, 2026

The role of antibody class and target on subepidermal blistering disease phenotype and management.

The role of antibody class and target on subepidermal blistering disease phenotype and management.

Journal: Italian journal of dermatology and venereology

Published: March 16, 2026

Cryptococcus neoformans Meningitis in a Patient With Epidermolysis Bullosa and Rheumatoid Arthritis.

Cryptococcus neoformans Meningitis in a Patient With Epidermolysis Bullosa and Rheumatoid Arthritis.

Journal: Cureus

Published: February 13, 2026

Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid.

Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid.

Journal: Biomolecules

Published: January 06, 2026

The Changing Trends in the Incidence and Clinical Presentation of Immunobullous Disorders Before and During the COVID-19 Era in a Tertiary Healthcare Centre in Andhra Pradesh.

The Changing Trends in the Incidence and Clinical Presentation of Immunobullous Disorders Before and During the COVID-19 Era in a Tertiary Healthcare Centre in Andhra Pradesh.

Journal: Cureus

Published: December 01, 2025

Immunomodulators and Antineoplastics Are Reported in Drug-Associated Epidermolysis Bullosa Acquisita Flares: A Retrospective Analysis of 58 Reported Cases Utilizing Multiple International Pharmacovigilance Databases.

Immunomodulators and Antineoplastics Are Reported in Drug-Associated Epidermolysis Bullosa Acquisita Flares: A Retrospective Analysis of 58 Reported Cases Utilizing Multiple International Pharmacovigilance Databases.

Journal: International journal of dermatology

Published: October 23, 2025

CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.

CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.

Journal: Molecular therapy. Advances

Published: October 13, 2025

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura.

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura.

Journal: Frontiers in immunology

Published: October 13, 2025

HLA genotype, clinical and immunofluorescence findings of 30 patients with type VII collagen antibody positive subepidermal bullous disease.

HLA genotype, clinical and immunofluorescence findings of 30 patients with type VII collagen antibody positive subepidermal bullous disease.

Journal: Clinical and experimental dermatology

Published: October 09, 2025

Type VII Collagen Disorders Simplified.

Type VII Collagen Disorders Simplified.

Journal: Cutis

Published: October 07, 2025

Showing 1-12 of 852

Last Updated: 09/26/2026